Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics

NEW YORK, June 27, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Akorn, Inc. (NASDAQ: AKRX), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Avanir Pharmaceuticals (NASDAQ: AVNR), Omeros Corporation (NASDAQ: OMER) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4189-100free.

Akorn, Inc. Analyst Notes
On June 20, 2014, Akorn, Inc. (Akorn) announced the completion of the sale of its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals for $41 million in cash and assumption of certain liabilities. Raj Rai, Akorn's CEO, commented, "While ECR is a solid platform of branded products, it is not a strategic fit to our business model of focusing on niche dosage forms. We believe this asset has better prospects for future growth and development under the leadership of a company like Valeant." According to the Company, in the light of the divestiture, Akorn will update its financial guidance during its Q2 FY 2014 earnings call, which is scheduled to be held in early August 2014. The full analyst notes on Akorn are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/AKRX/report.pdf

Merrimack Pharmaceuticals, Inc. Analyst Notes
On June 19, 2014, Merrimack Pharmaceuticals, Inc. (Merrimack) announced that it has reached an agreement with Sanofi to regain worldwide rights for the development and commercialization of MM-121, which is a monoclonal antibody designed to block ErbB3 (HER3) activation in patients with heregulin-positive tumors and improve response to standard of care treatments. "We are grateful for Sanofi's support over the last five years and believe that the data generated through this partnership validate the potential for MM-121 to help patients most at risk for progression on current therapies. Regaining MM-121 is an opportunity to capitalize on our leadership position among the other oncology companies that are pursuing ErbB3," said Robert Mulroy, President and CEO at Merrimack. "With these data and the feedback we've received from our committed investigators, we believe MM-121 has the potential to be a foundational therapy for use across multiple solid tumor types and we plan to continue its development through subsequent strategic partnerships. Our next step is to discuss our Phase 2 data and potential registration paths with the FDA." The full analyst notes on Merrimack are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/MACK/report.pdf

Avanir Pharmaceuticals Analyst Notes
On June 24, 2014, Avanir Pharmaceuticals, Inc. (Avanir) announced that it will present data in relation to the safety and efficacy of AVP-825, a Breath-Powered™ Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine. The Company informed that the data presentation will take place at the American Headache Society's 56th Annual Scientific Meeting, which will be held from June 26 to 29, 2014 in Los Angeles. The session entitled: A Randomized, Double-Blind, Double-Dummy, Active-Comparator Crossover Study of Breath-Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The COMPASS Study) will be held on June 28, 2014 at 12:30 p.m. PDTwhile the Breath-Powered Nasal Delivery of Sumatriptan Powder (AVP-825): An Exploratory Analysis of Response in Migraine Patients Grouped by Baseline Headache Intensity from the Phase 3 TARGET Study will be held on the same day on June 28, 2014 at 12:30 p.m. PDT. The full analyst notes on Avanir are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/AVNR/report.pdf

Omeros Corporation Analyst Notes
On June 24, 2014, Omeros Corp.'s stock increased 4.43% to end the day at $16.04 compared to the previous day's closing price of $15.36. The Company's stock increased 13.36% over the past five trading days compared to the Nasdaq Composite which rose 0.30% and compared to the Dow Jones Industrial Average which rose 0.06% during the same trading period. The full analyst notes on Omeros are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/OMER/report.pdf

TG Therapeutics, Inc. Analyst Notes
On June 24, 2014, TG therapeutics, Inc. (TG Therapeutics) announced that it has reached an agreement with Ligand Pharmaceuticals Inc. (Ligand) to license exclusive global rights for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitor research program. IRAK4 is a key component of signaling pathways, which regulate immune and inflammatory processes suggesting that inhibition of IRAK4 may also be useful in the treatment of autoimmune related disorders. Under the terms of agreement, Ligand will receive an up-front licensing fee of 125,000 unregistered shares of TG Therapeutics' common stock. In addition, TG Therapeutics will make development and sales-based milestone payments and will pay a tiered, mid-to-high single digit royalty on net sales. The full analyst notes on TG Therapeutics are available to download free of charge at:

http://www.analystsreview.com/Jun-27-2014/TGTX/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED